Razuprotafib

Please note, this OEL/ADE monograph also applies to Razuprotafib sodium (CAS RN 1809275-69-1). Razuprotafib, also known as AKB-9778, has been in development as a novel subcutaneous (SC) therapy for the treatment of diabetic eye disease. AKB-9778 is a small molecule that inhibits vascular endothelial protein tyrosine phosphatase (VE-PTP). This inhibition selectively increases the phosphorylation of tyrosine kinase with immunoglobulin-like and epidermal growth factor (EGF)-like domains 2 (Tie2) and augments Ang-1 signaling pathways through Tie2 that lead to vascular stabilization and protection against vascular leak and pathologic angiogenesis.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Razuprotafib

CAS Registry Number:
1008510-37-9
Synonym:
AKB-9778
Cost:
$679 USD

ADD TO CART

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

  • The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
  • A listing of all cited references utilized in the derivation of the OEL and ADE
  • An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

  • Fully documented. Over 20 pages in length, with calculations and cited references.
  • Save time! Unsurpassed delivery with instant download.
  • Save money. Similar documents cost 5-12 times as much.
  • Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for Razuprotafib, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.

Search OEL Fastrac

Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.

Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.
  • K. Rosenthal
  • Director of Manufacturing